- Home
- AORT vs MDXG Comparison
AORT vs MDXG Comparison
Compare AORT & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AORT
- MDXG
- Stock Information
- Founded
- AORT 1984
- MDXG 2006
- Country
- AORT United States
- MDXG United States
- Employees
- AORT N/A
- MDXG N/A
- Industry
- AORT Medical/Dental Instruments
- MDXG Biotechnology: Pharmaceutical Preparations
- Sector
- AORT Health Care
- MDXG Health Care
- Exchange
- AORT Nasdaq
- MDXG Nasdaq
- Market Cap
- AORT 1.4B
- MDXG 877.4M
- IPO Year
- AORT 1993
- MDXG N/A
- Fundamental
- Price
- AORT $30.86
- MDXG $6.98
- Analyst Decision
- AORT Strong Buy
- MDXG Strong Buy
- Analyst Count
- AORT 5
- MDXG 2
- Target Price
- AORT $32.40
- MDXG $12.50
- AVG Volume (30 Days)
- AORT 308.9K
- MDXG 649.3K
- Earning Date
- AORT 08-07-2025
- MDXG 07-30-2025
- Dividend Yield
- AORT N/A
- MDXG N/A
- EPS Growth
- AORT N/A
- MDXG N/A
- EPS
- AORT N/A
- MDXG 0.27
- Revenue
- AORT $390,084,000.00
- MDXG $352,375,000.00
- Revenue This Year
- AORT $12.18
- MDXG $9.55
- Revenue Next Year
- AORT $10.39
- MDXG $11.43
- P/E Ratio
- AORT N/A
- MDXG $25.81
- Revenue Growth
- AORT 5.94
- MDXG 5.34
- 52 Week Low
- AORT $21.97
- MDXG $5.47
- 52 Week High
- AORT $32.33
- MDXG $10.14
- Technical
- Relative Strength Index (RSI)
- AORT 61.03
- MDXG 69.74
- Support Level
- AORT $30.06
- MDXG $5.86
- Resistance Level
- AORT $30.85
- MDXG $6.42
- Average True Range (ATR)
- AORT 0.62
- MDXG 0.23
- MACD
- AORT -0.08
- MDXG 0.14
- Stochastic Oscillator
- AORT 62.04
- MDXG 94.68
About AORT Artivion Inc.
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.